You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMeclofenamic acid
Accession NumberDB00939  (APRD01090)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. [PubChem]
Structure
Thumb
Synonyms
Acide meclofenamique
Acido meclofenamico
Acidum meclofenamicum
CI-583
INF 4668
Meclofenamate
N-(2,6-Dichloro-3-methylphenyl)anthranilic acid
N-(2,6-Dichloro-m-tolyl)anthranilic acid
N-(3-Methyl-2,6-dichlorophenyl)anthranilic acid
External Identifiers
  • CI 583
  • Cl 583
  • INF 4668
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Meclofenamate SodiumCapsule50 mg/1OralMylan Pharmaceuticals Inc.1986-09-03Not applicableUs
Meclofenamate SodiumCapsule100 mg/1OralMylan Pharmaceuticals Inc.1986-09-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EthosYung Shin
EucomeU-Liang
MeclomenPfizer
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Meclofenamate sodium
ThumbNot applicableDBSALT001241
Categories
UNII48I5LU4ZWD
CAS number644-62-2
WeightAverage: 296.149
Monoisotopic: 295.016684015
Chemical FormulaC14H11Cl2NO2
InChI KeySBDNJUWAMKYJOX-UHFFFAOYSA-N
InChI
InChI=1S/C14H11Cl2NO2/c1-8-6-7-10(15)13(12(8)16)17-11-5-3-2-4-9(11)14(18)19/h2-7,17H,1H3,(H,18,19)
IUPAC Name
2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
SMILES
CC1=C(Cl)C(NC2=CC=CC=C2C(O)=O)=C(Cl)C=C1
Pharmacology
IndicationFor the relief of mild to moderate pain, for the treatment of primary dysmenorrhea and for the treatment of idiopathic heavy menstrual blood loss. Also for relief of the signs and symptoms of acute and chronic rheumatoid arthritis and osteoarthritis.
Structured Indications
PharmacodynamicsMeclofenamic acid is a nonsteroidal agent which has demonstrated anti-inflammatory, analgesic, and antipyretic activity in laboratory animals.
Mechanism of actionThe mode of action, like that of other nonsteroidal anti-inflammatory agents, is not known. Therapeutic action does not result from pituitary-adrenal stimulation. In animal studies, meclofenamic acid was found to inhibit prostaglandin synthesis and to compete for binding at the prostaglandin receptor site. In vitro meclofenamic acid was found to be an inhibitor of human leukocyte 5-lipoxygenase activity. These properties may be responsible for the anti-inflammatory action of meclofenamic acid. There is no evidence that meclofenamic acid alters the course of the underlying disease.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 1Proteinyes
inhibitor
HumanP23219 details
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Arachidonate 5-lipoxygenaseProteinyes
inhibitor
HumanP09917 details
Potassium voltage-gated channel subfamily KQT member 2Proteinunknown
other
HumanO43526 details
Potassium voltage-gated channel subfamily KQT member 3Proteinunknown
other
HumanO43525 details
Related Articles
AbsorptionRapidly absorbed in man following single and multiple oral doses with peak plasma concentrations occurring in 0.5 to 2 hours. The concomitant administration of antacids (aluminum and magnesium hydroxides) does not interfere with absorption of meclofenamic acid. Unlike most NSAIDs, which when administered with food have a decrease in rate but not in extent of absorption, meclofenamic acid is decreased in both. It has been reported that following the administration of meclofenamic acid capsules one-half hour after a meal, the average extent of bioavailability decreased by 26%, the average peak concentration (Cmax) decreased fourfold and the time to Cmax was delayed by 3 hours.
Volume of distribution
  • 9.1 to 43.2 L
Protein bindingGreater than 99% bound to plasma proteins over a wide drug concentration range.
Metabolism

Hepatic. Meclofenamic acid is extensively metabolized to an active metabolite (Metabolite I; 3-hydroxymethyl metabolite of meclofenamic acid) and at least six other less well characterized minor metabolites. Only Metabolite I has been shown in vitro to inhibit cyclooxygenase activity with approximately one fifth the activity of meclofenamic acid.

Route of eliminationOther metabolites, whose excretion rates are unknown, account for the remaining 35% to 62% of the dose excreted in the urine. The remainder of the administered dose (approximately 30%) is eliminated in the feces (apparently through biliary excretion). Trace amounts of meclofenamate sodium are excreted in human breast milk.
Half lifeIn a study in 10 healthy subjects following a single oral dose the apparent elimination half-life ranged from 0.8 to 5.3 hours. Metabolite I (3-hydroxymethyl metabolite of meclofenamic acid) has a mean half-life of approximately 15 hours.
Clearance
  • Oral cl=206 mL/min
ToxicityAfter a massive overdose, CNS stimulation may be manifested by irrational behavior, marked agitation and generalized seizures. Following this phase, renal toxicity (falling urine output, rising creatinine, abnormal urinary cellular elements) may be noted with possible oliguria or anuria and azotemia. A 24 year-old male was anuric for approximately one week after ingesting an overdose of 6 to 7 grams of meclofenamate sodium. Spontaneous diuresis and recovery subsequently occurred.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabMeclofenamic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololMeclofenamic acid may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aceclofenac.Approved
AcenocoumarolMeclofenamic acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinMeclofenamic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Meclofenamic acid.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.Approved
AliskirenMeclofenamic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololMeclofenamic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Amcinonide.Approved
AmikacinMeclofenamic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideMeclofenamic acid may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinMeclofenamic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodMeclofenamic acid may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Anisodamine.Investigational
annamycinMeclofenamic acid may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Antipyrine.Approved
Antithrombin III humanMeclofenamic acid may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Meclofenamic acid may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanMeclofenamic acid may increase the anticoagulant activities of Apixaban.Approved
ApramycinMeclofenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Apremilast.Approved, Investigational
ArbekacinMeclofenamic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinMeclofenamic acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanMeclofenamic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMeclofenamic acid may decrease the antihypertensive activities of Arotinolol.Approved
AtenololMeclofenamic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid.Approved
BalsalazideMeclofenamic acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminMeclofenamic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMeclofenamic acid may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Meclofenamic acid.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Meclofenamic acid.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Meclofenamic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololMeclofenamic acid may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betulinic Acid.Investigational
BevantololMeclofenamic acid may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
BisoprololMeclofenamic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMeclofenamic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMeclofenamic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Bucillamine.Investigational
BucindololMeclofenamic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide.Approved
BufuralolMeclofenamic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideMeclofenamic acid may decrease the diuretic activities of Bumetanide.Approved
BupranololMeclofenamic acid may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Meclofenamic acid.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Meclofenamic acid.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Meclofenamic acid.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Meclofenamic acid.Approved, Vet Approved, Withdrawn
CarteololMeclofenamic acid may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMeclofenamic acid may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Celecoxib.Approved, Investigational
CeliprololMeclofenamic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMeclofenamic acid may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Meclofenamic acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meclofenamic acid.Approved
CinoxacinMeclofenamic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinMeclofenamic acid may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidMeclofenamic acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Meclofenamic acid.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Meclofenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Curcumin.Investigational
CyclosporineMeclofenamic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with D-Limonene.Investigational
Dabigatran etexilateMeclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMeclofenamic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMeclofenamic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinMeclofenamic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinMeclofenamic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Meclofenamic acid.Approved
DextranMeclofenamic acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Meclofenamic acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Meclofenamic acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Meclofenamic acid may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Meclofenamic acid.Approved, Vet Approved
DicoumarolMeclofenamic acid may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid.Approved
DihydrostreptomycinMeclofenamic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Meclofenamic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Meclofenamic acid.Approved
DoxorubicinMeclofenamic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneMeclofenamic acid may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ebselen.Investigational
Edetic AcidMeclofenamic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMeclofenamic acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Meclofenamic acid.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Meclofenamic acid.Approved
EnoxacinMeclofenamic acid may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinMeclofenamic acid may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Epirizole.Approved
EpirubicinMeclofenamic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneMeclofenamic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Meclofenamic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilin.Approved
EsmololMeclofenamic acid may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone sulfate.Approved
Etacrynic acidMeclofenamic acid may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Meclofenamic acid.Approved, Investigational
Ethyl biscoumacetateMeclofenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Meclofenamic acid.Vet Approved
FleroxacinMeclofenamic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Meclofenamic acid.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fludrocortisone.Approved
FluindioneMeclofenamic acid may increase the anticoagulant activities of Fluindione.Investigational
FlumequineMeclofenamic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Meclofenamic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Meclofenamic acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Meclofenamic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxMeclofenamic acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMeclofenamic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Meclofenamic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Meclofenamic acid.Approved
FramycetinMeclofenamic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideMeclofenamic acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateMeclofenamic acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMeclofenamic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Meclofenamic acid.Approved, Withdrawn
GemifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinMeclofenamic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMeclofenamic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMeclofenamic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinMeclofenamic acid may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HE3286.Investigational
HeparinMeclofenamic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Higenamine.Investigational
HirulogMeclofenamic acid may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with HMPL-004.Investigational
HydralazineMeclofenamic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid.Approved
Hygromycin BMeclofenamic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Icatibant.Approved
IdarubicinMeclofenamic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxMeclofenamic acid may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Meclofenamic acid.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Meclofenamic acid.Approved
IndenololMeclofenamic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Meclofenamic acid.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Indoprofen.Withdrawn
INNO-206Meclofenamic acid may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Istaroxime.Investigational
KanamycinMeclofenamic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid.Approved
LabetalolMeclofenamic acid may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Leflunomide.Approved, Investigational
LepirudinMeclofenamic acid may increase the anticoagulant activities of Lepirudin.Approved
LevobunololMeclofenamic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMeclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Meclofenamic acid.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Meclofenamic acid.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Meclofenamic acid.Approved
LomefloxacinMeclofenamic acid may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Meclofenamic acid.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Meclofenamic acid.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Meclofenamic acid.Approved
ME-609The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with ME-609.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Meclofenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Meclofenamic acid.Approved, Vet Approved
MesalazineMeclofenamic acid may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMeclofenamic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.Approved
MetoprololMeclofenamic acid may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideMeclofenamic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Meclofenamic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Meclofenamic acid.Approved
MometasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Meclofenamic acid.Approved
MoxifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nabumetone.Approved
NadololMeclofenamic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMeclofenamic acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatMeclofenamic acid may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Meclofenamic acid.Approved
Nalidixic AcidMeclofenamic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Meclofenamic acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with NCX 4016.Investigational
NeamineMeclofenamic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinMeclofenamic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMeclofenamic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nepafenac.Approved
NetilmicinMeclofenamic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nitroaspirin.Investigational
NorfloxacinMeclofenamic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinMeclofenamic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.Approved
OlsalazineMeclofenamic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Meclofenamic acid.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Orgotein.Vet Approved
OtamixabanMeclofenamic acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.Approved
OxprenololMeclofenamic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Parecoxib.Approved
ParomomycinMeclofenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinMeclofenamic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMeclofenamic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololMeclofenamic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateMeclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Meclofenamic acid.Approved
PhenindioneMeclofenamic acid may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonMeclofenamic acid may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Meclofenamic acid.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Meclofenamic acid.Approved, Investigational
PindololMeclofenamic acid may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinMeclofenamic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideMeclofenamic acid may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Meclofenamic acid.Approved, Investigational
PlicamycinMeclofenamic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Meclofenamic acid.Approved
PractololMeclofenamic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Meclofenamic acid.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Propacetamol.Approved
PropranololMeclofenamic acid may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Meclofenamic acid.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Meclofenamic acid.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Meclofenamic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Meclofenamic acid.Vet Approved
Protein CMeclofenamic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanMeclofenamic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMeclofenamic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMeclofenamic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with PTC299.Investigational
PuromycinMeclofenamic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Meclofenamic acid.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Meclofenamic acid.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Meclofenamic acid.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Meclofenamic acid.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Resveratrol.Experimental, Investigational
ReviparinMeclofenamic acid may increase the anticoagulant activities of Reviparin.Approved
RibostamycinMeclofenamic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate.Approved, Investigational
RivaroxabanMeclofenamic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinMeclofenamic acid may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Meclofenamic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Meclofenamic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Meclofenamic acid.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Seratrodast.Approved, Investigational
SisomicinMeclofenamic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolMeclofenamic acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CMeclofenamic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinMeclofenamic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinMeclofenamic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Meclofenamic acid.Approved
SpironolactoneMeclofenamic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with SRT501.Investigational
StreptomycinMeclofenamic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinMeclofenamic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineMeclofenamic acid may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Meclofenamic acid.Approved
SulodexideMeclofenamic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Meclofenamic acid.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Meclofenamic acid.Approved, Withdrawn
TacrolimusMeclofenamic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Meclofenamic acid.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Meclofenamic acid.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Meclofenamic acid.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Meclofenamic acid.Approved, Investigational
TemafloxacinMeclofenamic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Meclofenamic acid.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Meclofenamic acid.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tiludronate.Approved, Vet Approved
TimololMeclofenamic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tixocortol.Approved
TobramycinMeclofenamic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Meclofenamic acid.Approved
TorasemideMeclofenamic acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Meclofenamic acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Meclofenamic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Meclofenamic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMeclofenamic acid may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trisalicylate-choline.Approved
TrovafloxacinMeclofenamic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Meclofenamic acid.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinMeclofenamic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Meclofenamic acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Meclofenamic acid.Approved
WarfarinMeclofenamic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMeclofenamic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Meclofenamic acid may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Meclofenamic acid.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Zomepirac.Withdrawn
ZorubicinMeclofenamic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food InteractionsNot Available
References
Synthesis Reference

U.S. Patent 3,313,848.

General ReferencesNot Available
External Links
ATC CodesM01AG04M02AA18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9393
Blood Brain Barrier+0.8668
Caco-2 permeable+0.8398
P-glycoprotein substrateNon-substrate0.806
P-glycoprotein inhibitor INon-inhibitor0.8943
P-glycoprotein inhibitor IINon-inhibitor0.9474
Renal organic cation transporterNon-inhibitor0.9094
CYP450 2C9 substrateNon-substrate0.6402
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.6566
CYP450 1A2 substrateInhibitor0.9236
CYP450 2C9 inhibitorInhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.8271
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.558
Ames testNon AMES toxic0.8633
CarcinogenicityNon-carcinogens0.5329
BiodegradationNot ready biodegradable0.9709
Rat acute toxicity3.0345 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9502
hERG inhibition (predictor II)Non-inhibitor0.872
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Quantum pharmics ltd
  • American therapeutics inc
  • Barr laboratories inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Usl pharma inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral50 mg/1
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point248-250U.S. Patent 3,313,848.
water solubility30 mg/LMERCK INDEX (1996)
logP5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00366 mg/mLALOGPS
logP5.11ALOGPS
logP6.09ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)3.79ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity76.45 m3·mol-1ChemAxon
Polarizability28.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
Substituents
  • Aminobenzoic acid
  • Benzoic acid
  • Aminotoluene
  • Substituted aniline
  • 1,3-dichlorobenzene
  • Benzoyl
  • Toluene
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Perez-Vizcaino F, Lopez-Lopez JG, Santiago R, Cogolludo A, Zaragoza-Arnaez F, Moreno L, Alonso MJ, Salaices M, Tamargo J: Postnatal maturation in nitric oxide-induced pulmonary artery relaxation involving cyclooxygenase-1 activity. Am J Physiol Lung Cell Mol Physiol. 2002 Oct;283(4):L839-48. [PubMed:12225961 ]
  2. Shiels IA, Whitehouse MW: Lyprinol: anti-inflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea. Allerg Immunol (Paris). 2000 Sep;32(7):279-83. [PubMed:11094641 ]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
  4. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181 ]
  5. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1993 Mar 25;268(9):6610-4. [PubMed:8454631 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ: Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. [PubMed:10639181 ]
  2. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens. 2002 Nov;20(11):2239-45. [PubMed:12409963 ]
  3. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222 ]
  4. Narsinghani T, Chaturvedi SC: QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):461-8. Epub 2005 Nov 14. [PubMed:16290292 ]
  5. Smith WL, Meade EA, DeWitt DL: Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. [PubMed:7825862 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediators from cultured bronchial epithelial cells. Am J Physiol. 1992 Feb;262(2 Pt 1):L229-34. [PubMed:1539679 ]
  2. Boctor AM, Eickholt M, Pugsley TA: Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro. Prostaglandins Leukot Med. 1986 Aug;23(2-3):229-38. [PubMed:3020588 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ3 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic in...
Gene Name:
KCNQ2
Uniprot ID:
O43526
Molecular Weight:
95846.575 Da
References
  1. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Voltage-gated potassium channel activity
Specific Function:
Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to sy...
Gene Name:
KCNQ3
Uniprot ID:
O43525
Molecular Weight:
96741.515 Da
References
  1. Peretz A, Degani N, Nachman R, Uziyel Y, Gibor G, Shabat D, Attali B: Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol. 2005 Apr;67(4):1053-66. Epub 2004 Dec 14. [PubMed:15598972 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S, Endou H: Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol. 1999 May;55(5):847-54. [PubMed:10220563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Westholm DE, Stenehjem DD, Rumbley JN, Drewes LR, Anderson GW: Competitive inhibition of organic anion transporting polypeptide 1c1-mediated thyroxine transport by the fenamate class of nonsteroidal antiinflammatory drugs. Endocrinology. 2009 Feb;150(2):1025-32. doi: 10.1210/en.2008-0188. Epub 2008 Oct 9. [PubMed:18845642 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23